宁夏中科生物科技股份有限公司：关于新增关联关系及2026年度日常关联交易预计的详细公告
一、公告重点摘要
- 公司公告新增重要关联方关系，并对2026年度与新关联方的日常关联交易进行预计，总金额不超过1,700万元人民币。
- 此次关联交易需提交公司股东大会审议，属于对未来经营有直接影响的重要事项。
- 公司与青岛合碳创物科技有限公司、海南海智源生命科技有限公司共同投资设立合资公司，注册资本2,000万元，公司出资580万元，占股29%，并由公司委派董事及财务负责人。
- 合资公司主营业务为藻油脂肪酸生产（包括DHA、EPA、DPA等）以及食品/饲料添加剂生产与技术研发。
- 预计2026年度“向关联方销售产品”金额1,500万元，“其他”类型交易金额200万元，合计不超过1,700万元，均为首次发生。
- 交易定价遵循市场化、公平合理原则，独立董事已表决通过，尚需股东大会进一步审议。
- 公司与关联人在业务、人员、资产、机构、财务等方面保持独立，本次交易不影响公司独立性，不会形成依赖或被控制。
二、详细内容解读
1. 新增关联方及投资事项
宁夏中科生物科技股份有限公司（ST宁科）与青岛合碳创物科技有限公司、海南海智源生命科技有限公司三方合作，拟共同设立一家有限责任公司（合资公司），三方分别出资1,020万元、580万元、400万元，对应持股比例为51%、29%、20%。公司将委派专人担任合资公司董事及财务负责人。
合资公司注册地暂定为宁夏石嘴山市惠农区，主要业务覆盖藻油脂肪酸产品（DHA、EPA等）以及食品/饲料添加剂的研发、生产、销售及相关技术服务和推广。
2. 关联交易预计及类型
预计2026年内，公司与上述关联方的日常关联交易将不超过1,700万元人民币，具体包括：
- 向合资公司销售产品：1,500万元，占同类业务100%；
- 其他（未具体说明，可能为技术或服务类）：200万元，占同类业务100%。
这些交易首次发生，因此本年初至披露日尚无累计发生金额，也无去年对标数据。
3. 交易审批与管理安排
上述关联交易事项已由董事会审议通过，独立董事已专门会议表决同意。因合资公司尚未设立，相关董事不适用关联回避情形。由于交易金额尚不明确，需提交股东大会进一步审议后方可执行。
合资公司不设监事会，仅设监事1名，董事会由4人组成（青岛合碳2人、公司1人、海南海智源1人），董事长和总经理均由青岛合碳推荐和委派，财务负责人由公司委派。
4. 定价原则与资金来源
关联交易定价将按照公平、公正、等价、有偿的市场化原则协商确定，确保不损害公司及中小股东的利益。合资公司各方出资均为自有资金。
5. 对公司及股东的影响
此次关联交易属于公司日常经营需要，有助于资源整合与产业链协同，进一步推动公司主营业务发展。公司表示与关联方在业务、资产、人员、财务等方面保持独立，合资公司不会影响公司的独立性，也不会导致公司对关联方形成依赖或被其控制。
三、股东需重点关注事项与潜在影响
- 本次新增关联交易及投资事项属于公司业务布局与扩张的重要举措，将直接影响公司未来收入结构及盈利能力。
- 股东大会的表决结果具有不确定性，相关事项落地与否将对公司经营预期及股价产生直接影响。
- 合资公司未来的经营成果及与公司之间的业务协同效果，将成为投资者关注的重点，且合资公司作为新设主体，存在一定的市场与运营风险。
- 此次交易首次发生，若后续业务快速推进，有望为公司带来新的利润增长点，具备一定的业绩弹性与想象空间，或成为影响公司估值的关键变量。
四、总结
综合来看，宁夏中科生物科技股份有限公司本次公告涉及新增关联关系及大额日常关联交易预计，伴随对外投资设立合资公司，属公司经营战略层面的重大变动。相关事项的最终实施和后续经营表现值得投资者密切关注，具有一定的股价催化潜力。
免责声明：本新闻稿仅供信息参考，相关内容不构成任何投资建议。投资者据此操作需自行承担风险。请关注公司后续正式公告及相关决议。
Ningxia Zhongke Biotechnology Co., Ltd.: Detailed Announcement on New Related Party Relationship and 2026 Routine Related Transactions
I. Key Highlights
- The company announced the addition of a key related party and forecasts routine related transactions with this party in 2026, totaling no more than RMB 17 million.
- The related transactions require shareholder meeting approval, marking a significant event with direct business impact.
- The company, together with Qingdao Hecarbon Technology Co., Ltd. and Hainan Haizhiyuan Life Technology Co., Ltd., will jointly invest in a new joint venture (JV), with registered capital of RMB 20 million. The company will contribute RMB 5.8 million for a 29% stake and will appoint a director and CFO.
- The JV’s main business: production of algal oil fatty acids (e.g., DHA, EPA, DPA) and food/feed additives, plus related technical R&D and services.
- Expected 2026 transactions: “sales to related party” RMB 15 million, “other” RMB 2 million, all first-time occurrences.
- Transaction pricing follows market-based, fair principles. The plan is approved by independent directors but requires further shareholder approval.
- The company and the related party remain independent in business, personnel, assets, structure, and finance. The JV will not affect company independence or cause dependency/control issues.
II. Detailed Analysis
1. New Related Party and Investment
Ningxia Zhongke Biotechnology Co., Ltd. (ST Ningke) is partnering with Qingdao Hecarbon and Hainan Haizhiyuan to establish a limited liability JV. The three parties will contribute RMB 10.2 million, RMB 5.8 million, and RMB 4 million for 51%, 29%, and 20% stakes, respectively. The company will appoint a director and CFO to the JV.
The JV, to be located in Huinong District, Shizuishan, Ningxia (tentative), will focus on algal oil fatty acids (DHA, EPA, etc.), food/feed additive R&D, production, sales, and related technical services.
2. Expected Related Transactions and Types
For 2026, the company expects routine related transactions with the JV not exceeding RMB 17 million:
- Sales to the JV: RMB 15 million (100% of similar business);
- Other (possibly technical or service-related): RMB 2 million (100%).
As these are first-time transactions, there is no year-to-date or prior-year comparison.
3. Transaction Approval and Management
The related transactions were approved by the board and independent directors; since the JV is not yet established, no director recusal was required. As the transaction amount is not yet finalized, shareholder meeting approval is pending.
The JV will not have a board of supervisors, only one supervisor. The board has four members (Qingdao Hecarbon 2, Company 1, Hainan Haizhiyuan 1), with chairman and GM appointed by Qingdao Hecarbon, and CFO by the company.
4. Pricing Principles and Funding
Transaction prices will be set fairly per market practice. Each party will use its own funds for capital contribution.
5. Impact on the Company and Shareholders
The transactions support the company’s day-to-day operations, facilitate resource integration, and enhance core business development. The company maintains independence from related parties, and the JV will not affect independence or cause reliance/control issues.
III. Key Issues for Shareholders and Potential Market Impact
- This new related party transaction and investment represent a strategic business move, directly affecting future revenue and profit structure.
- Shareholder meeting outcomes are uncertain; whether this plan moves forward will directly influence business outlook and share price.
- The JV’s future performance and business synergy with the company will be closely watched by investors. As a new entity, it faces market and operational risks.
- The transactions are first-time events; if business scales up quickly, this could become a new profit growth driver and a key variable in company valuation.
IV. Conclusion
In summary, this announcement covers the addition of a related party and a significant forecast for related transactions, along with a JV investment. It’s a major business strategy shift with potential market impact, and investors should closely monitor formal approvals and JV’s subsequent performance.
Disclaimer: This news is for informational purposes only and does not constitute investment advice. Investors should make decisions at their own risk and pay attention to subsequent company announcements and resolutions.
